211 related articles for article (PubMed ID: 11282190)
1. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.
Billaut-Mulot O; Idziorek T; Loyens M; Capron A; Bahr GM
Vaccine; 2001 Apr; 19(20-22):2803-11. PubMed ID: 11282190
[TBL] [Abstract][Full Text] [Related]
2. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
3. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
4. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine.
Billaut-Mulot O; Idziorek T; Ban E; Kremer L; Dupré L; Loyens M; Riveau G; Locht C; Capron A; Bahr GM
Vaccine; 2000 Aug; 19(1):95-102. PubMed ID: 10924791
[TBL] [Abstract][Full Text] [Related]
6. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.
Moore AC; Kong WP; Chakrabarti BK; Nabel GJ
J Virol; 2002 Jan; 76(1):243-50. PubMed ID: 11739689
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
8. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.
Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH
Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825
[TBL] [Abstract][Full Text] [Related]
9. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
10. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
11. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses.
Asakura Y; Lundholm P; Kjerrström A; Benthin R; Lucht E; Fukushima J; Schwartz S; Okuda K; Wahren B; Hinkula J
Biol Chem; 1999 Mar; 380(3):375-9. PubMed ID: 10223340
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.
Cazeaux N; Bennasser Y; Vidal PL; Li Z; Paulin D; Bahraoui E
Vaccine; 2002 Sep; 20(27-28):3322-31. PubMed ID: 12213402
[TBL] [Abstract][Full Text] [Related]
13. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
14. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
16. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
[TBL] [Abstract][Full Text] [Related]
17. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
20. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.
Huang Y; Chen Z; Zhang W; Gurner D; Song Y; Gardiner DF; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):403-11. PubMed ID: 18209683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
